ERBB2 and neoplasm: Through a series of preclinical studies, we showed that fluorophore-based DDSI of EGFR or HER2 provided high tumor-to-normal diagnostic performance, with an area under the curve (AUC) from receiver operator characteristic (ROC) curves routinely > 0.95 [35–38].